Akebia Therapeutics (AKBA) vs Evommune (EVMN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Akebia Therapeutics is the larger company by market cap ($242.0 million vs $225.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKBA | EVMN |
|---|---|---|
| Share price | $0.8734 | $6.22 |
| Market cap | $242.02M | $225.74M |
| 1-day change | -0.58% | -5.90% |
| YTD return | -45.75% | -63.67% |
| 1-year return | -70.39% | — |
| 5-year return | -69.35% | — |
| EPS (TTM) | $-0.12 | $-3.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.20 | $33.20 |
| 52-week low | $0.814 | $6.08 |
| Distance from 52-week high | -72.71% | -81.27% |
| Analyst consensus | none | buy |
| Avg. price target upside | +348.82% | +287.94% |
| Average volume | 6.09M | 675.52K |
| Shares outstanding | 277.11M | 36.29M |
| Employees | 194 | 48 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Healthcare · Drug Manufacturers - Specialty & Generic · 194 employees
About Evommune
EVMN stock →Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.
Healthcare · Biotechnology · 48 employees
AKBA vs EVMN FAQ
Which is bigger, Akebia Therapeutics or Evommune?
Akebia Therapeutics (AKBA) is larger, with a market capitalization of $242.02M compared with $225.74M for Evommune (EVMN).
Are Akebia Therapeutics and Evommune in the same industry?
Both are in the Healthcare sector, but in different industries: Drug Manufacturers - Specialty & Generic for Akebia Therapeutics and Biotechnology for Evommune.